Olanzapine and Fluoxetine combination (OFC) + Fluoxetine
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment Resistant Depression
Conditions
Treatment Resistant Depression
Trial Timeline
Aug 1, 2009 → Mar 1, 2012
NCT ID
NCT00958568About Olanzapine and Fluoxetine combination (OFC) + Fluoxetine
Olanzapine and Fluoxetine combination (OFC) + Fluoxetine is a phase 3 stage product being developed by Eli Lilly for Treatment Resistant Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT00958568. Target conditions include Treatment Resistant Depression.
What happened to similar drugs?
3 of 20 similar drugs in Treatment Resistant Depression were approved
Approved (3) Terminated (4) Active (13)
🔄HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00958568 | Phase 3 | Completed |
Competing Products
20 competing products in Treatment Resistant Depression